Detalles de la búsqueda
1.
Text and Mobile Media Smoking Cessation Service for Young Adults in South Texas: Operation and Cost-Effectiveness Estimation.
Health Promot Pract
; 18(4): 581-585, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28438055
2.
Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder.
Int Psychogeriatr
; 27(9): 1533-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25925598
3.
Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
J Clin Psychopharmacol
; 34(4): 461-6, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24977716
4.
Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
Crohns Colitis 360
; 6(1): otae001, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38313767
5.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
Inflamm Bowel Dis
; 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271613
6.
Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
J Clin Psychopharmacol
; 33(6): 766-74, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23963057
7.
Mitral valve replacement combined with coronary artery bypass graft surgery in patients with moderate-to-severe ischemic mitral regurgitation.
Rev Port Cardiol
; 32(2): 131-7, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23333215
8.
Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room.
Health Qual Life Outcomes
; 9: 18, 2011 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-21447155
9.
Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.
J Clin Psychopharmacol
; 30(2): 145-51, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20520287
10.
Executive Functioning Outcomes Over 6 Months of Atomoxetine for Adults With ADHD: Relationship to Maintenance of Response and Relapse Over the Subsequent 6 Months After Treatment.
J Atten Disord
; 24(3): 363-372, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27521574
11.
Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy.
Neuropsychiatr Dis Treat
; 15: 809-817, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31040680
12.
Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study.
Atten Defic Hyperact Disord
; 9(2): 113-120, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28058589
13.
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.
Neuropsychiatr Dis Treat
; 13: 2115-2124, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28831260
14.
An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis.
Neuropsychiatr Dis Treat
; 13: 2105-2114, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28831259
15.
Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Atten Defic Hyperact Disord
; 9(4): 219-229, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28477289
16.
Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder.
Neuropsychiatr Dis Treat
; 12: 89-97, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26811681
17.
Efficacy comparison of duloxetine and SSRIs at doses approved in Japan.
Neuropsychiatr Dis Treat
; 11: 115-23, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25624763
18.
Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
Postgrad Med
; 127(7): 677-85, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26329980
19.
Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder.
Eur Neuropsychopharmacol
; 25(10): 1611-21, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26169574
20.
Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.
Atten Defic Hyperact Disord
; 6(1): 25-34, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24142305